Additionally, in comparison to Prox-1 and LYVE-1, it is more sensitive in recognizing lymphangiogenesis in breast cancer and displays the strongest immunoreactivity in both intratumoral and peritumoral LECs (39–41). Here, LYVE1 is linked to breast carcinoma.